2 February 2022 LungLife AI, Inc. (the “Company” or “LungLife”) First patient enrolment for LungLB® validation study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has enrolled its first patient in its pivotal clinical study to evaluate the LungLB® test in subjects presenting with indeterminate lung nodules. The […]
4 January 2022 LungLife AI, Inc. (the “Company” or “LungLife”) CPT® Code granted by American Medical Association Successful grant marks first step facilitating commercial reimbursement LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT® Proprietary Laboratory Analyses (PLA) code for its LungLB® […]
LungLife AI licensure/accreditation information posted here.